MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM)

Biomedicine and Pharmacotherapy

Volumn 88, Issue , 2017, Pages 507-514

  Fan, Xuelong ^a,b   Zhou, Shangcheng ^c   Zheng, Miao ^d   Deng, Xiyun ^a   Yi, Yinsha ^a   Huang, Tieniu ^b,e  

^a HUNAN NORMAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Department of Endocrine and Vascular Surgery   (China)

^d Anbu Overseas Chinese Hospital of Chaoan County of Guangdong Province   (China)

^e Xiangtan Medicine Health Vocational College   (China)

Author keywords

Apoptosis; Breast cancer; Chemotherapy resistance; Cisplatin; MicroRNAs; TFAM

Indexed keywords

CISPLATIN; MESSENGER RNA; MICRORNA; MICRORNA 199A 3P; MITOCHONDRIAL DNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; MIRN199 MICRORNA, HUMAN; MITOCHONDRIAL PROTEIN; TFAM PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MDA-MB-231 CELL LINE; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA, MITOCHONDRIAL; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MITOCHONDRIAL PROTEINS; TRANSCRIPTION FACTORS;

EID: 85010190235     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.01.058     Document Type: Article

References (36)

1. [1] Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., Parkin, D.M., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127:12 (2010), 2893–2917.
2. [2] Kaufmann, M., von Minckwitz, G., Bear, H.D., Buzdar, A., McGale, P., Bonnefoi, H., Colleoni, M., Denkert, C., Eiermann, W., Jackesz, R., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann. Oncol. 18:12 (2007), 1927–1934.
3. [3] Silver, D.P., Richardson, A.L., et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28:7 (2010), 1145–1153.
4. [4] Florea, A.-M., Büsselberg, D., Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3:1 (2011), 1351–1371.
5. [5] Lynam-Lennon, N., Maher, S.G., Reynolds, J.V., The roles of microRNA in cancer and apoptosis. Biol. Rev. 84:1 (2009), 55–71.
6. [6] Fendler, A., Jung, M., Stephan, C., Honey, R.J., Stewart, R.J., Pace, K.T., Erbersdobler, A., Samaan, S., Jung, K., Yousef, G.M., miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. Int. J. Oncol. 39:5 (2011), 1183–1192.
7. [7] Garofalo, M., Quintavalle, C., Romano, G., Croce, C.M., Condorelli, G., miR221/222 in cancer: their role in tumor progression and response to therapy. Curr. Mol. Med. 12:1 (2012), 27–33.
8. [8] Lu, Z., Ye, Y., Jiao, D., Qiao, J., Cui, S., Liu, Z., miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncol. Lett. 4:5 (2012), 1027–1032.
9. [9] Wang, Q., Li, P., Li, A., Wei, J., Hong, W., Wang, J., Xie, K., Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J. Exp. Clin. Cancer Res. 31:2 (2012), 1–10.
10. [10] He, H., Ge, J., Dong, J., Wang, L., Effect of miR-199a-5ptransfection on the growth of clear-cell renal-cell carcinoma 786-0 cells. J. Med. Postgrad. 26:9 (2013), 921–924.
11. [11] Li, S.Q., Wang, Z.H., Mi, X.G., Liu, L., Tan, Y., MiR-199a/b-3p suppresses migration and invasion of breast cancer cells by downregulating PAK4/MEK/ERK signaling pathway. IUBMB Life 67:10 (2015), 768–777.
12. [12] Murakami, Y., Yasuda, T., Saigo, K., Urashima, T., Toyoda, H., Okanoue, T., Shimotohno, K., Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25:17 (2006), 2537–2545.
13. [13] Li, S.D., Zhang, J.R., Wang, Y.Q., Wan, X.P., The role of microRNAs in ovarian cancer initiation and progression. J. Cell. Mol. Med. 14:9 (2010), 2240–2249.
14. [14] Song, G., Zeng, H., Li, J., Xiao, L., He, Y., Tang, Y., Li, Y., miR-199a regulates the tumor suppressor mitogen-activated protein kinase kinase kinase 11 in gastric cancer. Biol. Pharm. Bull. 33:11 (2010), 1822–1827.
15. [15] Yi, H., Liang, B., Jia, J., Liang, N., Xu, H., Ju, G., Ma, S., Liu, X., Differential roles of miR-199a-5p in radiation-induced autophagy in breast cancer cells. FEBS Lett. 587:5 (2013), 436–443.
16. [16] Deng, S., Tang, S., Zhang, S., Zhang, C., Wang, C., Zhou, Y., Dai, C., Xiao, X., Furazolidone induces apoptosis through activating reactive oxygen species-dependent mitochondrial signaling pathway and suppressing PI3K/Akt signaling pathway in HepG2 cells. Food Chem. Toxicol. 75 (2015), 173–186.
17. [17] Thyagarajan, B., Wang, R., Barcelo, H., Koh, W.P., Yuan, J.M., Mitochondrial copy number is associated with colorectal cancer risk. Cancer Epidemiol. Biomark. Prev. 21:9 (2012), 1574–1581.
18. [18] Kukat, C., Davies, K.M., Wurm, C.A., Spåhr, H., Bonekamp, N.A., Kühl, I., Joos, F., Polosa, P.L., Park, C.B., Posse, V., Cross-strand binding of TFAM to a single mtDNA molecule forms the mitochondrial nucleoid. Proc. Natl. Acad. Sci. U. S. A. 112:36 (2015), 11288–11293.
19. [19] Zehowski, C., Manipulating Tfam Expression and Mitochondrial Capacity to Overcome Drug Resistance in Breast Cancer Cells. 2012, Undergraduate Research Opportunities Program.
20. [20] Zheng, T., Wang, J., Chen, X., Liu, L., Role of microRNA in anticancer drug resistance. Int. J. Cancer 126:1 (2010), 2–10.
21. [21] Bar, N., Dikstein, R., miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One, 5(5), 2010, e10859.
22. [22] Greene, S.B., Gunaratne, P.H., Hammond, S.M., Rosen, J.M., A putative role for microRNA-205 in mammary epithelial cell progenitors. J. Cell Sci. 123:4 (2010), 606–618.
23. [23] Pogribny, I.P., Filkowski, J.N., Tryndyak, V.P., Golubov, A., Shpyleva, S.I., Kovalchuk, O., Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int. J. Cancer 127:8 (2010), 1785–1794.
24. [24] Hou, J., Lin, L., Zhou, W., Wang, Z., Ding, G., Dong, Q., Qin, L., Wu, X., Zheng, Y., Yang, Y., Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19:2 (2011), 232–243.
25. [25] Kong, Y.W., Ferland-McCollough, D., Jackson, T.J., Bushell, M., microRNAs in cancer management. Lancet Oncol. 13:6 (2012), e249–e258.
26. [26] Ueda, T., Volinia, S., Okumura, H., Shimizu, M., Taccioli, C., Rossi, S., Alder, H., Liu, C.-G., Oue, N., Yasui, W., Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 11:2 (2010), 136–146.
27. [27] Wang, Z., Ting, Z., Li, Y., Chen, G., Lu, Y., Hao, X., microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin. Oncol. Lett. 6:3 (2013), 789–794.
28. [28] Xu, N., Zhang, J., Shen, C., Luo, Y., Xia, L., Xue, F., Xia, Q., Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem. Biophys. Res. Commun. 423:4 (2012), 826–831.
29. [29] Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Calin, G.A., Grazi, G.L., Pollutri, D., Croce, C.M., Bolondi, L., Gramantieri, L., MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 70:12 (2010), 5184–5193.
30. [30] Kang, D., Kim, S.H., Hamasaki, N., Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions. Mitochondrion 7:1–2 (2007), 39–44.
31. [31] Mambo, E., Chatterjee, A., Xing, M., Tallini, G., Haugen, B.R., Yeung, S.C.J., Sukumar, S., Sidransky, D., Tumor-specific changes in mtDNA content in human cancer. Int. J. Cancer 116:6 (2005), 920–924.
32. [32] Gaspari, M., Larsson, N.G., Gustafsson, C.M., The transcription machinery in mammalian mitochondria. Biochim. Biophys. Acta 1659:2–3 (2005), 148–152.
33. [33] Han, B., Izumi, H., Yasuniwa, Y., Akiyama, M., Yamaguchi, T., Fujimoto, N., Matsumoto, T., Wu, B., Tanimoto, A., Sasaguri, Y., Human mitochondrial transcription factor A functions in both nuclei and mitochondria and regulates cancer cell growth. Biochem. Biophys. Res. Commun. 408:1 (2011), 45–51.
34. [34] Yao, J., Zhou, E., Wang, Y., Xu, F., Zhang, D., Zhong, D., microRNA-200a inhibits cell proliferation by targeting mitochondrial transcription factor A in breast cancer. DNA Cell Biol. 33:5 (2014), 291–300.
35. [35] Gao, W., Wu, M.H., Wang, N., Ying, M.Z., Zhang, Y.Y., Hua, J., Chuan, L., Wang, Y.J., Mitochondrial transcription factor A contributes to cisplatin resistance in patients with estrogen receptor-positive breast cancer. Mol. Med. Rep. 14:6 (2016), 5304–5310.
36. [36] Kutanzi, K.R., Yurchenko, O.V., Beland, F.A., Checkhun, V.F., Pogribny, I.P., MicroRNA-mediated drug resistance in breast cancer. Clin. Epigenet. 2:2 (2011), 171–185.